Literature DB >> 11508276

High prevalence of glucokinase mutations in Italian children with MODY. Influence on glucose tolerance, first-phase insulin response, insulin sensitivity and BMI.

O Massa1, F Meschi, A Cuesta-Munoz, A Caumo, F Cerutti, S Toni, V Cherubini, L Guazzarotti, N Sulli, F M Matschinsky, R Lorini, D Iafusco, F Barbetti.   

Abstract

AIMS/HYPOTHESIS: The aim of this study was to assess the prevalence of glucokinase gene mutations in Italian children with MODY and to investigate genotype/phenotype correlations of the mutants.
METHODS: Screening for sequence variants in the glucokinase gene was performed by denaturing gradient gel electrophoresis and direct sequencing in 132 children with maturity onset diabetes of the young (MODY) and in 9 children with chronic fasting hyperglycaemia but without laboratory evidence for Type I (insulin-dependent) diabetes mellitus and with normoglycaemic parents ("non-classical" MODY).
RESULTS: Altogether 54 mutations were identified in the MODY group (54/132 or 41%) and 3 among the "non-classical" MODY individuals (3/9 or 33%). Paternity testing indicated that the latter mutations have arisen de novo. Mean fasting plasma glucose concentrations of the children with the mutant glucokinase was in the expected impaired fasting glucose range. In contrast, results of the oral glucose tolerance test showed a wide range from normal glucose tolerance (Group 1: 2-h OGTT = 6.7 +/- 1.1 mmol/l; 11 patients) to diabetes (Group 2: 2-h OGTT = 11.5 +/- 0.5 mmol/l; 9 patients), with the remaining in the impaired glucose tolerance range. Disruptive mutations (i.e. nonsense, frameshifts, splice-site) were equally represented in Groups 1 and 2 and were not clearly associated with an impaired first-phase insulin response. Surprisingly, 5 out of 11 children (or 45%) in Group 1 were found to be overweight but no children in Group 2 were overweight. Sensitivity index (SI), calculated by a recently described method, was found to be significantly lower in Group 2 than in Group 1 (SI Group 2 = 0.0013 +/- 0.0009 ml Kg(-1) min(-1)/muU/ml; SI Group 1 = 0.0068 +/- 0.0048, p < 0.0035). CONCLUSION/
INTERPRETATION: Mutations in glucokinase are the first cause of MODY among Italian children selected through a low threshold limit of fasting plasma glucose (i. e. > 5.5 mmol). The lack of correlation between the molecular severity of glucokinase mutations, insulin secretion at intravenous glucose tolerance test and differences in glucose tolerance suggests that factors outside the beta cell are also involved in determining post-load glucose concentrations in these subjects. Our results seem to indicate that the differences observed in the 2-h responses at the OGTT among children with MODY 2 could be related to individual differences in insulin sensitivity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11508276     DOI: 10.1007/s001250100530

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  38 in total

1.  Lack of glibenclamide response in a case of permanent neonatal diabetes caused by incomplete inactivation of glucokinase.

Authors:  Josep Oriola; Francisca Moreno; Angel Gutiérrez-Nogués; Sara León; Carmen-María García-Herrero; Olivier Vincent; María-Angeles Navas
Journal:  JIMD Rep       Date:  2015-02-10

2.  Prevalence of GCK mutations in individuals screened for fasting hyperglycaemia.

Authors:  A L Gloyn; M van de Bunt; I M Stratton; L Lonie; L Tucker; S Ellard; R R Holman
Journal:  Diabetologia       Date:  2008-11-11       Impact factor: 10.122

3.  Opposite clinical phenotypes of glucokinase disease: Description of a novel activating mutation and contiguous inactivating mutations in human glucokinase (GCK) gene.

Authors:  Fabrizio Barbetti; Nadia Cobo-Vuilleumier; Carlo Dionisi-Vici; Sonia Toni; Paolo Ciampalini; Ornella Massa; Pablo Rodriguez-Bada; Carlo Colombo; Lorenzo Lenzi; María A Garcia-Gimeno; Francisco J Bermudez-Silva; Fernando Rodriguez de Fonseca; Patrizia Banin; Juan C Aledo; Elena Baixeras; Pascual Sanz; Antonio L Cuesta-Muñoz
Journal:  Mol Endocrinol       Date:  2009-11-02

4.  Genetic epidemiology of MODY in the Czech republic: new mutations in the MODY genes HNF-4alpha, GCK and HNF-1alpha.

Authors:  S Pruhova; J Ek; J Lebl; Z Sumnik; F Saudek; M Andel; O Pedersen; T Hansen
Journal:  Diabetologia       Date:  2003-01-08       Impact factor: 10.122

5.  Effects of novel maturity-onset diabetes of the young (MODY)-associated mutations on glucokinase activity and protein stability.

Authors:  María Galán; Olivier Vincent; Isabel Roncero; Sharona Azriel; Pedro Boix-Pallares; Elías Delgado-Alvarez; Francisco Díaz-Cadórniga; Enrique Blázquez; María-Angeles Navas
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

6.  Molecular genetic testing of patients with monogenic diabetes and hyperinsulinism.

Authors:  James T Bennett; Valeria Vasta; Min Zhang; Jaya Narayanan; Peter Gerrits; Si Houn Hahn
Journal:  Mol Genet Metab       Date:  2014-12-20       Impact factor: 4.797

7.  Beta cell function and insulin sensitivity in obese youth with maturity onset diabetes of youth mutations vs type 2 diabetes in TODAY: Longitudinal observations and glycemic failure.

Authors:  Silva Arslanian; Laure El Ghormli; Morey H Haymond; Christine L Chan; Steven D Chernausek; Rachelle G Gandica; Rose Gubitosi-Klug; Lynne L Levitsky; Maggie Siska; Steven M Willi
Journal:  Pediatr Diabetes       Date:  2020-03-03       Impact factor: 4.866

8.  Quantitative mass spectrometry of diabetic kidney tubules identifies GRAP as a novel regulator of TGF-beta signaling.

Authors:  Timothy D Cummins; Michelle T Barati; Susan C Coventry; Sarah A Salyer; Jon B Klein; David W Powell
Journal:  Biochim Biophys Acta       Date:  2009-10-22

9.  Maturity-onset diabetes of the young in children with incidental hyperglycemia: a multicenter Italian study of 172 families.

Authors:  Renata Lorini; Catherine Klersy; Giuseppe d'Annunzio; Ornella Massa; Nicola Minuto; Dario Iafusco; Christine Bellannè-Chantelot; Anna Paola Frongia; Sonia Toni; Franco Meschi; Franco Cerutti; Fabrizio Barbetti
Journal:  Diabetes Care       Date:  2009-06-29       Impact factor: 17.152

Review 10.  Undiagnosed MODY: Time for Action.

Authors:  Jeffrey W Kleinberger; Toni I Pollin
Journal:  Curr Diab Rep       Date:  2015-12       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.